Assuntos
Antimetabólitos Antineoplásicos/efeitos adversos , Capecitabina/efeitos adversos , Carcinoma/secundário , Mielite/etiologia , Radiodermite/etiologia , Radioterapia Adjuvante/efeitos adversos , Neoplasias da Coluna Vertebral/secundário , Vértebras Torácicas , Antimetabólitos Antineoplásicos/uso terapêutico , Antineoplásicos Fitogênicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/radioterapia , Neoplasias da Mama/cirurgia , Capecitabina/uso terapêutico , Carcinoma/tratamento farmacológico , Carcinoma/radioterapia , Carcinoma/cirurgia , Terapia Combinada , Docetaxel/uso terapêutico , Substituição de Medicamentos , Feminino , Humanos , Oxigenoterapia Hiperbárica , Letrozol/uso terapêutico , Pessoa de Meia-Idade , Mielite/induzido quimicamente , Mielite/diagnóstico por imagem , Mielite/terapia , Miosite/diagnóstico por imagem , Miosite/etiologia , Prednisolona/uso terapêutico , Radiodermite/induzido quimicamente , Radiodermite/diagnóstico por imagem , Radiodermite/terapia , Medula Espinal/efeitos da radiação , Neoplasias da Coluna Vertebral/radioterapiaRESUMO
Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, prostate, gastric, head and neck, and ovarian cancers, as well as in the adjuvant setting for operable node-positive breast cancers. Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent one of the major AEs associated with these agents. With an increase in the occurrence of cutaneous AEs during treatment with novel targeted and immunological therapies when used in combination with taxanes, a thorough understanding of reactions attributable to this class is imperative. Moreover, identification and management of dermatological AEs is critical for maintaining the quality of life in cancer patients and for minimizing dose modifications of their antineoplastic regimen. This analysis represents a systematic review of the dermatological conditions reported with the use of these drugs, complemented by experience at comprehensive cancer centres. The conditions reported herein include skin, hair, and nail toxicities. Lastly, we describe the dermatological data available for the new, recently FDA-and EMA- approved, solvent-free nab-paclitaxel.
Assuntos
Antineoplásicos/efeitos adversos , Toxidermias/etiologia , Paclitaxel/efeitos adversos , Taxoides/efeitos adversos , Alopecia/induzido quimicamente , Docetaxel , Edema/induzido quimicamente , Humanos , Lúpus Eritematoso Cutâneo/induzido quimicamente , Doenças da Unha/induzido quimicamente , Transtornos da Pigmentação/induzido quimicamente , Radiodermite/induzido quimicamenteRESUMO
Phototherapy recall can occur unexpectedly as a result of treatment with commonly used medications and chemotherapy. These reactions are rare. The recall reaction is an inflammatory response that is triggered by many medications. Cyclophosphamide and docetaxel are widely used chemotherapeutic agents that are useful in the management of many different malignancies. The pathophysiology of phototherapy recall is not clearly understood. This case highlights the need for practitioners to be aware of this potential reaction, even though UV exposure may have occurred in the distant past. We present, to the best of our knowledge, the first phototherapy recall dermatitis that occurred years after UV exposure induced by cyclophosphamide and docetaxel. The frequency of administration of this drug and the profound implications of this adverse effect make this case an important contribution to the medical literature.
Assuntos
Ciclofosfamida/efeitos adversos , Fototerapia/efeitos adversos , Radiodermite/induzido quimicamente , Taxoides/efeitos adversos , Antineoplásicos/efeitos adversos , Docetaxel , Quimioterapia Combinada/efeitos adversos , Feminino , Humanos , Pessoa de Meia-Idade , Fatores de TempoRESUMO
BACKGROUND: Methotrexate (MTX), alongside fumaric acid esters, is the most commonly used drug in the systemic therapy of psoriasis in Germany. It is sometimes used in combination with topical therapy and/or phototherapy due to synergistic effects. CASE REPORT: Here we describe a case of phototoxic dermatitis during treatment with MTX. Other cutaneous side effects of MTX include so-called UV recall, radiation recall, and skin tumor formation.
Assuntos
Metotrexato/efeitos adversos , Transtornos de Fotossensibilidade/induzido quimicamente , Transtornos de Fotossensibilidade/diagnóstico , Psoríase/terapia , Terapia Ultravioleta , Adulto , Artrite Psoriásica/terapia , Terapia Combinada , Humanos , Masculino , Metotrexato/uso terapêutico , Neoplasias Induzidas por Radiação/induzido quimicamente , Neoplasias Induzidas por Radiação/diagnóstico , Neoplasias Induzidas por Radiação/terapia , Transtornos de Fotossensibilidade/terapia , Radiodermite/induzido quimicamente , Radiodermite/diagnóstico , Radiodermite/terapia , Fatores de Risco , Neoplasias Cutâneas/induzido quimicamente , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/terapia , Terapia Ultravioleta/efeitos adversosAssuntos
Anlodipino/efeitos adversos , Neoplasias da Mama/radioterapia , Fluorbenzenos/efeitos adversos , Mastectomia Segmentar , Pirimidinas/efeitos adversos , Radiodermite/induzido quimicamente , Radiodermite/diagnóstico , Radioterapia Adjuvante/efeitos adversos , Sulfonamidas/efeitos adversos , Anlodipino/administração & dosagem , Antibacterianos/administração & dosagem , Anti-Hipertensivos/efeitos adversos , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Carcinoma in Situ/radioterapia , Carcinoma Ductal de Mama/radioterapia , Carcinoma Lobular/radioterapia , Celulite (Flegmão)/diagnóstico , Celulite (Flegmão)/tratamento farmacológico , Diagnóstico Diferencial , Fracionamento da Dose de Radiação , Esquema de Medicação , Feminino , Fluorbenzenos/administração & dosagem , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Pirimidinas/administração & dosagem , Rosuvastatina Cálcica , Sulfonamidas/administração & dosagem , Fatores de TempoRESUMO
Small molecule tyrosine kinase inhibitors are rapidly being integrated into the management of cancer. This is the first report of sorafenib and sunitinib, both small molecule tyrosine kinase inhibitors of vascular endothelial growth factor and platelet-derived growth factor receptors, triggering radiation recall dermatitis. The pathophysiology of radiation recall is poorly understood, and several possible mechanisms have been proposed. The clinical presentations of these two cases were consistent with one hypothesized mechanism of radiation recall, an idiosyncratic drug hypersensitivity reaction.